American College of Medical Toxicology Spring 2009 Newsletter|
The newsletter is always looking for new material to publish. Is there an interesting story that you think would be of interest to the membership? A picture or photograph from a national meeting that you'd like to share? Is there a story of toxicologic interest that you think would be important to disseminate to the members? The newsletter is your voice - let it be heard!
Requests for new features, ideas, content and images can be sent at anytime to email@example.com. If you have an interest in helping with the editorial process of the newsletter, please contact us as well.
||What's New on ACMT.net|
- Save your login information
- Renew your membership dues
- Apply for Fellow status
- Discover one of our many educational conferences
- Participate in a discussion on the Forum
Help wanted for the following:
- Internet Library of Images in Toxicology (ILIT)
- Educational Content
Suggestions appreciated at firstname.lastname@example.org
Dr. Michael Shannon
At the time this newsletter goes to press, ACMT received the news that former ACMT President Michael Shannon, MD died suddenly, collapsing at a New York City airport after returning from a trip to Argentina. ACMT is incredibly saddened by this unbelievable loss. Michael was one of Medical Toxicology's and ACMT's true "Giants." Michael exemplified the highest standards both professionally and personally. He was a role model to so many of us and will be missed very much. ACMT extends its deepest sympathies to Michael's wife, Elaine, and his two children, Evan and Lila.
ACMT will provide tribute to Michael's life in a future newsletter.
| ||ACMT's Important Role in Fostering the Growth of Medical Toxicology|
Erica L. Liebelt, MD, FACMT
Since, the inception of the American College of Medical Toxicology 16 years ago in 1993, the growth and credibility of Medical Toxicology as a medical subspecialty has been significant. The College has continually strived to promote the practice of medical toxicology.
In my last Presidents' Column, I gave my thoughts on WHAT and WHO is ACMT? Most importantly, ACMT is its members and its physician members serve an important role in advancing quality care of poisoned patients and public health in numerous and varied roles.
The College has implemented numerous initiatives to help foster the growth of our specialty. Remember ACMT is its members and ACMT will help its members to further advance our specialty!
Fostering the growth of collaborative research and a national toxicology patient registry through bedside physician toxicologists
Under the leadership of Paul Wax, MD, FACMT (Executive Director) and Jeffrey Brent, MD, FACMT (Chair, Practice Committee), ACMT has implemented a new and exciting initiative that will undoubtedly improve the collection, accuracy, and validity of clinical data regarding poisoning and adverse drug events. ACMT's new research and surveillance network, ToxIC or Toxicology Investigators Consortium, is a voluntary group of medical toxicologists who share the common interest of seeing patients at the bedside and who are interested in pursuing collaborative research and/or surveillance activities. We are currently in the process of setting a strategic mission and objectives for the upcoming year. In addition, we have already initiated collaboration with non-medical toxicologist subspecialties to provide our toxicology expertise in other areas including oncology, anesthesia, and medication safety.
ACMT Mentorship Program
Fostering the growth of fellows-in-training and early career medical toxicologists
Under the direction of Ann-Jeannette Geib, MD and Jeffrey Brent, MD, ACMT is pleased to announce the launching of its Mentorship Program! The intent of the program is to provide guidance and career development for fellows-in-training and early career medical toxicologists (in addition to that already provided by fellowship programs). Mentorship has been shown to increase career satisfaction and advancement among both parties involved. We are now recruiting eager, pioneering members to serve as mentors in the pilot portion of the Mentorship Program. If you have any questions about this please feel free to contact Ann-Jeanette.
LLSA Activity in Puerto Rico and San Antonio
Fostering the continued growth of board-certified medical toxicologists
ACMT, in collaboration with AACT, announced the inauguration of the first Lifelong Learning and Self-Assessment (LLSA) session at the ACMT Spring Meeting this March in Puerto Rico on March 27 or 28. To maintain the viability of our subspecialty, it is critical that medical toxicologists maintain their board certification in medical toxicology. The LLSA is one of the four components of the Maintenance of Certification process. We will be collaborating with AACT for a similar LLSA Session at the 2009 NACCT meeting in San Antonio.
ACMT Forensic Toxicology Course
Fostering collaboration between ACMT and other professional organizations for the professional development of our members
ACMT is proud to announce our first forensic toxicology course developed in collaboration with the Society of Forensic Toxicology (SOFT). Because the subspecialty of medical toxicology interfaces with numerous other specialties, it is important that we not only foster collaborations to advance the specialty, but also to provide professional development for our members for the growth of our clinical practices and potential additional career opportunities. This conference is targeted toward medical, clinical, forensic and laboratory toxicologists, and others with an interest in the legal aspects of intoxication with a focus on ethanol and marijuana issues.
Formation of three ACMT Practice Interest Groups
Fostering the growth of Medical Toxicology in clinical settings
Medical toxicology is a subspecialty that offers numerous opportunities for professional development and careers outside of academic centers, acute-care hospital settings, and poison center activities. I feel it is important for our members to have the opportunity to carry on dialogue among other members who are practicing in the similar arenas and/or members who may be interested in pursuing what we might have thought 10 years ago as non-traditional medical toxicology careers. My thanks to the following ACMT members who have agreed to chair these three interest groups:
Industry: Dan Goldstein, MD, FACMT (email@example.com)
Government: Curtis Snook, MD, FACMT (firstname.lastname@example.org)
Military: David Tanen, MD, FACMT (email@example.com)
These groups can serve as another means of providing our expertise to other healthcare sectors in this country by promoting the exchange of ideas among members with similar interests. Please contact these chairs if you are interested in learning more about a career or are already practicing in these areas.
|Vaccines and Autism - Decisions
The long awaited decisions from the Federal Omnibus Hearings on the validity of the purported link between autism and thimerosal and/or MMR vaccines was released in a series of three decisions on February 12, 2009. These very detailed and extensive decisions, reached after months of scientific testimony, completely rejected any relationship between vaccines and autism.
Jeffrey Brent, M.D., Ph.D., a long time ACMT member and current member of the College's Board of Directors, is a consultant to the US Government on vaccine safety. He recently provided the scientific testimony on the lack of the relationship between thimerosal exposure and autism on behalf of the government. Importantly, the role of medical toxicologists in issues such as this was highlighted in all three decisions.
In one of the decisions US Special Master George Hastings discussed Jeff's qualifications (modified here from page 24)
"Respondent [the US Government] countered Dr. Aposhian [referring to Vas Aposhian, Ph.D.] chiefly with the expert report and hearing testimony of Dr. Jeffrey Brent, M.D., Ph.D., who is a physician and Clinical Professor of Pediatrics and Internal Medicine at the University of Colorado. Although Dr. Aposhian has excellent credentials and experience in the area of "toxicology" -- that is, the study of the adverse effects of chemical substances on living systems -- Dr. Brent has even more impressive qualifications to opine in this area. Dr. Brent, unlike Dr. Aposhian, is a medical doctor. Further, Dr. Brent is a medical toxicologist, which means that he has specific and extensive medical training concerning the effects of poisons on the human system. He is one of about 250 board-certified medical toxicologists in the United States, and he has experience in treating children with actual mercury toxicity."
In a second decision in another of the Omnibus Hearings (see here) US Special Master Denise Vowell took note of the importance of medical toxicology as a sub-specialty in several places. For example, one of the petitioners experts incorrectly described herself as a "medical toxicologist" and was characterized by Special Master Vowell as "resume padding."
Regarding the actual toxicological testimony, the opinion noted (slightly modified from p. 30):
"Three witnesses with excellent qualifications testified on the subject of mercury toxicology: Dr. Aposhian for petitioners, and Drs. Brent and McCabe for respondents. Although Dr. Byers offered some testimony on mercury toxicology, she lacked the qualifications to opine credibly on this topic. Doctors Aposhian, Brent, and McCabe all had impressive qualifications in their fields. In evaluating their testimony, I considered Dr. Brent's greater qualifications as a medical toxicologist. I also found his testimony on mercury's effects much more credible than that of Dr. Aposhian, who, after testifying about the various species of mercury, tended to conflate their effects. The difference between a toxicologist and a medical toxicologist is significant.
Medical toxicologists are medical doctors who must complete a two-year post-residency fellowship in an accredited medical toxicology program and must pass a certifying examination. In contrast, there are no certifications or educational requirements for toxicologists. There are about 250 board certified medical toxicologists in the U.S. Doctor Brent is one of them; Dr. Aposhian is not. Doctor McCabe, is not a medical toxicologist, but he is an immunotoxicologist, with 20 years of metal immunotoxicology experience and with impeccable qualifications in this field. He testified primarily about the significance of Colten's mercury testing."
The third decision in the Omnibus hearings (see here) was written by Special Master Patricia Campbell-Smith. Here too, the importance of medical toxicology was highlighted (slightly modified) on p.13-14:
"Dr. Brent is a clinical professor of Pediatrics and Internal Medicine at the University of Colorado Health Sciences Center in Denver. He also maintains a private, single-specialty, group practice under the name of Toxicology Associates, the focus of which practice is to "deal solely with issues related to medical toxicology." Dr. Brent is one of approximately 250 board-certified medical toxicologists in the United States. As explained during the Cedillo trial, a board-certified medical toxicologist is distinguishable from a toxicologist (such as Dr. Aposhian), for whom there are no formal requirements. Eligibility for certification by the American Board of Medical Specialties in the subspecialty of medical toxicology is based on completing a primary residency in a clinical field, a subsequent two-year full-time medical toxicology subspecialty fellowship in an accredited program, and then the medical toxicology medical certifying examination. Board certification in the subspecialty of medical toxicology is conferred upon the successful completion of the certifying examination. Dr. Brent treats patients for mercury toxicity and has presented on the topic of mercury toxicity. Dr. Brent testified during the Cedillo hearing. His testimony was credible and well-informed. His facility with the scientific literature was very helpful to the undersigned."
Congratulations and thanks to Jeff for his help in raising the visibility and credibility of our very small specialty.
|ToxIC - Introducing the Toxicology Investigators Consortium|
Recently the College sent out a member survey to inventory the diffusion of medical toxicology into bedside care. The results were nothing short of astonishing. Based on those responses, there are at least 69 medical toxicology practices providing in-patient bedside care to between 15 and 20 thousand patients annually. These patients are not seen while working in an ED or by taking poison center calls, but rather in our role as an in-hospital specialty consultant. Large, but significantly smaller, numbers of outpatients are seen by many of these practices.
This is obviously a great thing for patients with toxicological problems and it also highlights the potential we have to do multi-center studies. Because most respondents to our survey indicated that they would be interested in participating in such studies, ToxIC was formed. The first major foray into toxicological research of our network is a potential collaboration with the Research on Adverse Drug Events and Report (RADAR) project, based at Northwestern University. This project has had NIH funding for over 10 years to study adverse drug events (ADEs). Their focus has been on oncological drugs and their funding has come from the National Cancer Institute (NCI). The RADAR group and the College have joined forces to study these ADEs in a detailed fashion by doing complete bedside evaluations by medical toxicologists. This collaboration should very substantially enhance the quality and hence the understanding of these ADEs. All practices in ToxIC were invited to participate in this research and a subgroup of 39 responded. This subgroup has been designated the ToxOnc network. In early February the RADAR group and the College submitted an R01 grant to the NCI for funding of the ToxOnc network. We are now awaiting the results of this submission. If funded, this will provide financial support to the ToxOnc investigators.
Given the potential of the ToxIC network, the ToxOnc project is likely the first of many studies that can be done. ACMT will develop initiatives in which any ToxIC investigator may choose to participate. The College also invites all investigators in the network to come up with their own research ideas and concepts utilizing the ToxIC. If you have a practice that does patient care and evaluation at the bedside, in a clinic, or both, have not yet joined ToxIC, and are interested in participating, please let Tricia Steffey know (firstname.lastname@example.org.) Questions about ToxIC can be addressed to Jeff Brent (email@example.com), Lewis Nelson (firstname.lastname@example.org) or Paul Wax (email@example.com).
We hope to get a small kick-off luncheon together for ToxIC investigators at the ACMT Spring Course in Puerto Rico. Hopefully a more formal meeting will be arranged during NACCT.
|ACMT's First Forensics Course - Save the Date!
||7th Annual ACMT Spring Conference 2009|
November 18 & 19, 2009
Sheraton Inner Harbor Hotel—Baltimore, Maryland
This conference is targeted toward medical, clinical, forensic and laboratory toxicologists, and others with an interest in the legal aspects of intoxication. The conference goal is to provide an intensive course on the forensic aspects of ethanol and marijuana. Leaders in the field will cover issues pertaining to biochemistry, toxicokinetics, clinical effects, and laboratory analysis and interpretation of these widely available intoxicants. Recent advances in understanding the neurobiology of impairment will be presented. Issues related to the choice of matrix (blood, urine, oral fluid and hair) will be analyzed. Special emphasis will be given to a thorough understanding of the scientific basis for the assumptions, modeling, and calculations used in these cases. Small group, interactive, and multimedia presentations will be used to enhance the curriculum.
Planning Committee: Marilyn Huestis, PhD; Barry Logan, PhD; Charles McKay, MD, FACMT; Lewis Nelson, MD, FACMT; Paul Wax, MD, FACMT.
Look for conference details on the website, late March.
March 27 & 28, 2009
San Juan Marriott Resort & Stellaris Casino, Puerto Rico
“Neurotoxicology Update: Advances, Challenges & Future Directions”
to attend the 7th Annual ACMT Spring Conference being held in beautiful
San Juan, Puerto Rico. The conference will deliver cutting edge
concepts relative to neurotoxic mechanisms, controversies, and
etiologies for Parkinsonism, cognitive disorders, neuropathy and
autism; case-based presentations on pesticide, mercury and lead
toxicity; and the practical use and interpretation of
neuropsychological testing, EMG, and nerve conduction studies.
Register for the 2009 Spring Conference today by going to the ACMT website, or by calling (623) 533-6340.
Click here for the Spring Course brochure.
|New! LLSA Session Added To Spring Conference 2009
To facilitate preparation for the first Lifelong Learning and
Self-Assessment (LLSA) test offered by the American Board of Emergency
Medicine (available June 2009), ACMT in collaboration with AACT has added a
special session that will provide a review of each of the 12 articles that will be covered during the first LLSA test. This LLSA preparatory session will be held from 2:30 PM to 5:00 PM on the second day of the conference, March 28, 2009, at no additional cost to conference registrants. More information about the LLSA and the Medical Toxicology maintenance of certification program can be found here.
The articles covered by this year's LLSA (from the Core Content of Medical Toxicology) are:
from Toxins and Toxicants
Content Area 2.1: Drugs
Boyer EW, Shannon M. The serotonin syndrome. N Eng J Med. Mar 2005; 352 (11): 1112-1120.
Kao LW, Furbee RB. Drug-induced Q-T prolongation. Med Clin N Am. 2005; 89: 1125-1144.
Schade R, Andersohn F, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. Jan 2007; 356 (1): 29-38.
Traub SJ, Hoffman RS, Nelson LS. Body packing - the internal concealment of illicit drugs. N Engl J Med. Dec 2003; 349 (26): 2519-2526.
Selections from Remaining Content Areas
Content Area 1.0: Principles of Toxicology
Roth BL. Drugs and valvular heart disease. N Engl J Med. Jan
2007; 356 (1): 6-9.
Content Area 2.2: Industrial, Household, and Environmental Toxicants
Henry CR, Satran D, et al. Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning. JAMA. Jan 2006; 295 (4): 398-402.
Content Area 2.3: Natural Products
Enjalbert F, Rapior S, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol. 2002; 40 (6): 715-757.
Escudie L, Francoz C, et al. Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatology. 2007; 46: 466-473.
Content Area 3.0: Therapeutics
Hall AH, Dart R, Bogdan G. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning. Ann Emerg Med. June 2007; 49 (6): 806-813.
Megarbane B, Karyo S, Baud FJ. The role of insulin and glucose (hyperinsulinaemia/euglycaemia) therapy in acute calcium channel antagonist and
beta-blocker poisoning. Toxicol Rev 2004; 23 (4): 215-222.
Content Area 5.0: Analytical and Forensic Toxicology
Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology. Sept 2002; 36 (3): 659-665.
Leikin JB, Watson WA. Post-mortem toxicology: what the dead can and cannot tell us. J Toxicol Clin Toxicol 2003; 41 (1): 47
|Fellows Mentoring Program
||Virtual Mentorship Advisor Program|
What is mentorship? It is a professional relationship between one who is more experienced and one more junior in a particular field. Paramount is an environment of trust and confidentiality. Effective mentoring relationships tend to have clearly defined goals and timelines, and may focus on achieving a specific task, or the overall career pathway. While traditional professional mentoring relationships take place face-to-face, the availability of the internet may be exploited to bridge geography and bring participants together. Mentorship has been shown to increase career satisfaction for both parties involved and improves career advancement for the mentee. Mentors also benefit by the infusion of new information and enthusiasm from the protege.
ACMT emphasizes that the mentorship program is designed to augment and only accentuate the full breadth of the many high-quality fellowship programs. We will be opening up participation to early-career Toxicologists who wish to benefit from the program.
The ACMT Mentorship Program will be launching shortly. Some dedicated mentors already have offered to participate in this important program. We always welcome more! If you are willing to participate, please send a letter of interest and a biosketch to firstname.lastname@example.org.
We also are recruiting those who think they may benefit from mentorship - at any career stage. Please feel free to contact me at any time!
At present, there are approximately 300 ABEM-certified medical toxicologists in the United States. Because of these small numbers, students, residents, and faculty at many of the 126 US medical schools and Emergency Medicine residency training programs do not have personal access to mentorship by medical toxicologists.
This is a 'virtual mentor' program to serve medical students, emergency medicine residents, and physicians who express an interest in medical toxicology but who do not have access to a medical toxicologist at their home institutions.
The Virtual Mentorship for Toxicology Training Program was developed in coordination and partnership with the SAEM Toxicology Interest Group, the American College of Emergency Medicine, and the American College of Medical Toxicology. This site will provide information about the specialty of medical toxicology, provide information about medical toxicology training opportunities including:
- Rotations that accept visiting residents/students
- Research opportunities
- Accredited fellowship programs
- A mechanism to facilitate one-on-one 'virtual advisor' relationships between EM/toxicology faculty members and interested students/residents/physicians.
The American College of Medical Toxicology Fellowship Group has offered to provide mentorship to interested medical students and physicians.
If you are an interested medical student or physician in learning more about this program or participating in this program, please contact the Program Coordinator, David C. Lee, MD at email@example.com.
Healthy People in a Healthy Environment
2009 National Environmental Public Health Conference
October 26 - 28, 2009
Sheraton Atlanta Hotel, Atlanta, GA
Who: People interested in the interrelationship between the environment and health: federal, state, tribal, and local public and environmental health professionals, academic researchers; physicians, nurses, and other healthcare professionals; representatives from communities and organizations; policy and decision makers.
What: Exploring new research and innovative practice in ecosystems and public health, healthy places and communities, sustainability, public health and chemical exposures, and more.
Centers for Disease Control and Prevention's National Center for Environmental Health and the Agency for Toxic Substances and Disease Registry & National Environmental Health Association
ACMT is a member of the organizing committee and is represented by our Executive Director, Paul Wax, MD.
|International Committee Update
Since its revival in the summer of 2008, the International Committee has focused much of its efforts on building its infrastructure, both at the central and peripheral levels. A well-organized leadership structure is key to facilitating our ongoing efforts to create a global network of collaborators and provide the ACMT with the right channels to engage in bilateral exchanges in the areas of clinical practice, education and research. To keep you abreast of the developments within our group, I have outlined some of our more recent achievements.
I am proud to announce that we have successfully recruited Regional Directors (RD) for four of the six WHO regions who will be responsible for engaging our international colleagues and monitoring activities in their designated regions. Through them, our Committee has already identified several Ambassadors at the local level in almost every region. To facilitate internal and external collaborations in our three areas of interest, the International Committee has created the Education, Research Consortium, and Best Practice Subcommittees. Lastly, to oversee the development of our Committee and help identify sources of funding for our projects, a Development Subcommittee was also founded.
Latin America: Javier Waksman, RD for the Americas, is collaborating with our local members on upcoming educational activities and identifying means by which we, as a U.S.-based entity, can better understand the region's profile and learn from their extensive experience in the field.
Middle East: Through the leadership of Ziad Kazzi, RD for the Eastern Mediterranean, our group has secured an entire day at the upcoming Dubai International Emergency & Catastrophe Management Conference in April 2009 to offer a toxicology symposium. ACMT members and local experts will be presenting a wide range of talks relevant to the region's toxicologic environment.
Africa: Josef Thundiyil, RD for Africa, and I are working with the Toxicology Society of South Africa to include an ACMT symposium at their upcoming 7th Congress of Toxicology in Developing Countries in September 2009.
South East Asia: Rais Vohra, RD for SE Asia, will be touring nations in the region in the coming months to identify local experts and help us better assess the needs through the formulation of a needs assessment tool.
Online CME: With the support of our colleagues from the Education and Web site Committees, we will be preparing a plan to offer online courses, via the ACMT site, to our international members. This will allow colleagues from resource-limited regions to access educational content for quality improvement and personal development purposes.
Membership Dues: In the coming months, we will work with the Membership Committee to devise a tiered membership dues process, based on the World Bank's stratification, to further facilitate access to ACMT by international colleagues.
Facebook: To follow-up on Paul Wax’s ingenious idea, I have also started a Facebook group for the Committee allowing us to expand our online presence and facilitate discussions among our members. Registration on Facebook is free of charge and the group's site can be accessed here.
Through your invaluable support and dedication, ACMT will be in a far better position to understand what the world has to offer and how we can be of support to developing systems. I therefore invite you all to join this exciting adventure, if you haven’t already done so, and hope that it’ll be as fruitful and enriching to you as it has been for me. Lastly, I would very much like to get a sense of how you envision our Committee’s future role and whether there are other projects you’d like us to engage in. As always, feel free to shoot me an email anytime.
Nadeem Al-Duaij, MD
Chair | International Committee
Congratulations to the new leadership of the Medical Toxicology Fellows-in-Training Association (MTFITA)!
The new leaders are:
President -- Chris Rosenbaum
University of Massachusetts Medical Center
Vice-President -- Danny Lugassy
New York City Poison Control Center
Secretary/Treasurer -- Keenan Bora
Detroit, MI - Children's Regional Poison Center
Education Director -- Michael Levine
Banner Health-Good Samaritan Medical Center, Phoenix
Website Director -- Jennifer Boyle
University of Virginia, Charlottesville
We, the current leadership (Chip Gresham - VP; Banner Health-Good Sam, Phoenix, AZ, Spence Greene - Educational Director; Banner Health-Good Sam, Phoenix, AZ, and I) are excited to have Chris, Danny, Keenan, Michael, and Jen aboard and are confident they will lead the MTFITA in new directions with greater zeal. Each fellow is commendable for simply stepping up and volunteering to guide this organization. We know there are others who were willing to lead as well, and we thank them. We recognize that we are all busy, so it is wonderful to have our friends and colleagues show their determination and take charge to improve camaraderie in the Association and expand our efforts in promoting education, research, and transition to the medical toxicology community.
The MTFITA website is preparing to launch, and we are excited to post information, educational material, and other useful items to fellows. We are grateful to Dr. Howard Greller for his work in setting up the MTFITA website.
Chip Gresham, Spencer Greene, and I will continue to work with the new leadership through the through the end of the academic year. The change of leadership will occur at the ACMT Spring Course in Puerto Rico later this month. Dr. Paul Wax will announce the new leaders.
Again, congratulations to the new leadership selected from many outstanding toxicology fellows. We are confident they will do an outstanding job in their new roles. As always, we look forward to all of the fellowsí participation in the Association by way of contributing ideas, educational material, and anything you deem profitable for the other fellows.
Thanks for your support.
Shawn Varney, MD
2009 ACMT/McNeil Products Award for Acetaminophen-Related Research|
The American College of Medical Toxicology is now accepting applications for the 2009 ACMT/McNeil Products Award for Acetaminophen-Related Research.
The purpose of this award is to support new acetaminophen-related research.
The award is $7,500 to provide funding support for one suitable research project. This grant does not provide for institutional overhead.
- The principal investigator must be an active ACMT member. Fellows-in-training are encouraged to apply.
- Any in vitro, animal, or human studies must conform and be approved by the applicants local institutional ethics committee.
- Research involving acetaminophen containing OTC analgesic products and acetaminophen-combination products are permitted.
Applicants are required to electronically submit 1 blinded (all identifying information removed) and 1 unblinded copy of the project description including:
- Background and Significance
- Specific Aims
- Research Design and Methods
- A proposed timetable for the study
- A biosketch for each investigator (NIH biographical sketch format)
- Fellows-in-training must include a letter of support from their program director and project mentor
The ACMT research committee will review and score applications on five areas:
- Scientific Importance
- Clear Hypothesis and Specific Aim(s)
- Methodology/Experimental Design
- Feasibility of completion
- Travel expenses to present study results at NACCT are permissible
- Proposals must be NO LONGER than 5 single spaced pages (excluding references) with a minimum font size of 11
- The winner of the 2009 ACMT/McNeil Products Award for Acetaminophen-Related Research is expected to submit their results for presentation at either the ACMT Spring Course or the North American Congress of Clinical Toxicology
- A one year progress report is required for multiyear proposals
- Applicants requiring additional funds to carry out their proposal must submit a letter of financial commitment from the co-supporting person/institution
- The winner must acknowledge funding support by ACMT/McNeil Products in publications resulting from their research project
- The winner is encouraged to submit their study results to the ACMT Journal of Medical Toxicology
The winner will be requested to sign a Letter of Agreement stating they agree to adhere to all guidelines outlined above.
APPLICATION DEADLINE: May 30, 2009
Please email your application to: Daniel E. Rusyniak, MD
||ACMT Newsletter Photo Caption Contest!|
Welcome to the first ACMT newsletter contest. No cost to enter! Submit as many times as you want! Win acclaim and prizes!
Rules for caption contest . . .
- Email a caption for the picture (to the left) to firstname.lastname@example.org
- Do this before April 15th, 2009
- Repeat, as necessary
The winner will be published in the next edition of the newsletter.